Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL

Journal of Medical Case Reports Pub Date : 2024-12-21 DOI:10.1186/s13256-024-04986-2

Kasım Okan, Ragıp Fatih Kural, Meryem Demir, Furkan Cot, Mustafa Dinckal, Sevgi Altay, Nihal Mete Gökmen

{"title":"Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report.","authors":"Kasım Okan, Ragıp Fatih Kural, Meryem Demir, Furkan Cot, Mustafa Dinckal, Sevgi Altay, Nihal Mete Gökmen","doi":"10.1186/s13256-024-04986-2","DOIUrl":null,"url":null,"abstract":"Background: Postorgasmic illness syndrome is characterized by flu, rhinitis, conjunctivitis, loss of appetite, muscle weakness, and fatigue after ejaculation, lasting 2-7 days. The multidisciplinary treatment approach, incorporating omalizumab and antidepressants, has rarely been documented in literature.Case presentation: In this article, we present the case of a 33-year-old single Turkish male with postorgasmic illness syndrome, characterized by typical clinical symptoms and a positive autologous semen test. Notably, his serum estrogen and progesterone levels were elevated. The patient's Beck anxiety score was 42 points, the depression scale score was 37, and suicidal thoughts. Fresh autologous semen taken at the hospital was diluted with 0.9% saline, and prick and intradermal skin tests were performed.Conclusion: The patient's symptoms improved significantly with the combination of omalizumab and escitalopram. This case not only provides a new perspective on the management of postorgasmic illness syndrome but also highlights the potential roles of allergic, psychiatric, and endocrinological mechanisms in the etiology and treatment of this complex condition.","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"18 1","pages":"632"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662807/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-024-04986-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Postorgasmic illness syndrome is characterized by flu, rhinitis, conjunctivitis, loss of appetite, muscle weakness, and fatigue after ejaculation, lasting 2-7 days. The multidisciplinary treatment approach, incorporating omalizumab and antidepressants, has rarely been documented in literature.

Case presentation: In this article, we present the case of a 33-year-old single Turkish male with postorgasmic illness syndrome, characterized by typical clinical symptoms and a positive autologous semen test. Notably, his serum estrogen and progesterone levels were elevated. The patient's Beck anxiety score was 42 points, the depression scale score was 37, and suicidal thoughts. Fresh autologous semen taken at the hospital was diluted with 0.9% saline, and prick and intradermal skin tests were performed.

Conclusion: The patient's symptoms improved significantly with the combination of omalizumab and escitalopram. This case not only provides a new perspective on the management of postorgasmic illness syndrome but also highlights the potential roles of allergic, psychiatric, and endocrinological mechanisms in the etiology and treatment of this complex condition.

查看原文本刊更多论文

性高潮后疾病综合征受益于奥玛单抗和抗抑郁药：一个病例报告。

背景：高潮后疾病综合征以流感、鼻炎、结膜炎、食欲不振、肌肉无力、射精后疲劳为特征，持续2-7天。多学科治疗方法，结合奥玛珠单抗和抗抑郁药，很少有文献记载。病例介绍：在这篇文章中，我们提出了一个33岁的土耳其男性性高潮后疾病综合征的病例，其特点是典型的临床症状和阳性的自体精液测试。值得注意的是，他的血清雌激素和黄体酮水平升高。患者的贝克焦虑得分为42分，抑郁量表得分为37分，还有自杀念头。取医院新鲜自体精液，用0.9%生理盐水稀释，进行点刺和皮内皮肤试验。结论：奥马单抗与艾司西酞普兰合用可显著改善患者的症状。本病例不仅为性高潮后疾病综合征的治疗提供了新的视角，而且强调了过敏、精神病学和内分泌学机制在这一复杂疾病的病因和治疗中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Case Reports Medicine-Medicine (all)

CiteScore

1.50

自引率

0.00%

发文量

436

期刊介绍： JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect